Patents by Inventor Rashmi Narendrula

Rashmi Narendrula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR DETERMINING EFFICACY OF CHEMOTHERAPY TREATMENT FOR A SUBJECT
    Publication number: 20220028489
    Abstract: Various embodiments are described herein related to an assay, method and apparatus for performing an RNA Disruption Assay (RDA) for cellular RNA optionally in response to a cytotoxic treatment such as chemotherapy and/or radiation treatment. The method comprises obtaining at least one electropherogram dataset corresponding to a unique biological sample comprising the cellular RNA at a time point, optionally during or after the treatment; determining values for features from at least two shifted regions of the at least one electropherogram dataset, the shifting being due to the treatment; and optionally determining an RDA score based on a combination of the values of the features.
    Type: Application
    Filed: June 4, 2021
    Publication date: January 27, 2022
    Inventors: Kenneth Pritzker, Amadeo Mark Parissenti, Laura Pritzker, Mu Zhu, Xiaohui Wang, Stacey Santi, Rashmi Narendrula, Baoqing Guo
  • Method for determining efficacy of chemotherapy treatment for a subject
    Patent number: 11031096
    Abstract: Various embodiments are described herein related to an assay, method and apparatus for performing an RNA Disruption Assay (RDA) for cellular RNA optionally in response to a cytotoxic treatment such as chemotherapy and/or radiation treatment. The method comprises obtaining at least one electropherogram dataset corresponding to a unique biological sample comprising the cellular RNA at a time point, optionally during or after the treatment; determining values for features from at least two shifted regions of the at least one electropherogram dataset, the shifting being due to the treatment; and optionally determining an RDA score based on a combination of the values of the features.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: June 8, 2021
    Assignee: RNA DIAGNOSTICS INC.
    Inventors: Kenneth Pritzker, Amadeo Mark Parissenti, Laura Pritzker, Mu Zhu, Xiaohui Wang, Stacey Santi, Rashmi Narendrula, Baoqing Guo
  • Methods and kits for monitoring response to radiation therapies in cancer
    Patent number: 10385400
    Abstract: A method of evaluating a cancer cell sample, the method comprising: a. obtaining a cancer cell sample, optionally a breast cancer cell sample or an ovarian cancer cell sample, after the cancer cells have been exposed to a radiation dose; b. assaying the cancer cell sample to obtain a RNA integrity value and/or a RNA concentration of the cancer cell sample.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: August 20, 2019
    Assignee: RNA DIAGNOSTICS INC.
    Inventors: Mu Zhu, Amadeo Mark Parissenti, Laura Pritzker, Kenneth Pritzker, Stacey Santi, Baoqing Guo, Xiaohui Wang, Rashmi Narendrula
  • Methods and Kits for Monitoring Response to Radiation Therapies in Cancer
    Publication number: 20150315656
    Abstract: A method of evaluating a cancer cell sample, the method comprising: a. obtaining a cancer cell sample, optionally a breast cancer cell sample or an ovarian cancer cell sample, after the cancer cells have been exposed to a radiation dose; b. assaying the cancer cell sample to obtain a RNA integrity value and/or a RNA concentration of the cancer cell sample.
    Type: Application
    Filed: December 3, 2013
    Publication date: November 5, 2015
    Inventors: Mu Zhu, Amadeo Mark Parissenti, Laura Pritzker, Kenneth Pritzker, Stacey Santi, Baoqing Guo, Xiaohui Wang, Rashmi Narendrula
  • ASSAYS, METHODS AND APPARATUS FOR ASSESSING RNA DISRUPTION
    Publication number: 20150154350
    Abstract: Various embodiments are described herein related to an assay, method and apparatus for performing an RNA Disruption Assay (RDA) for cellular RNA optionally in response to a cytotoxic treatment such as chemotherapy and/or radiation treatment. The method comprises obtaining at least one electropherogram dataset corresponding to a unique biological sample comprising the cellular RNA at a time point, optionally during or after the treatment; determining values for features from at least two shifted regions of the at least one electropherogram dataset, the shifting being due to the treatment; and optionally determining an RDA score based on a combination of the values of the features.
    Type: Application
    Filed: April 24, 2013
    Publication date: June 4, 2015
    Inventors: Kenneth Pritzker, Amadeo Mark Parissenti, Laura Pritzker, Mu Zhu, Xiaohui Wang, Stacey Santi, Rashmi Narendrula, Baoqing Guo